NDAORALTABLET
Approved
Jan 2023
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
BRENZAVVY (bexagliflozin) by TheracosBio is sodium-glucose transporter 2 inhibitors [moa]. Approved for sodium-glucose cotransporter 2 inhibitor [epc]. First approved in 2023.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRENZAVVY (bexagliflozin) is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor approved by the FDA on January 20, 2023, for the treatment of type 2 diabetes. It works by inhibiting renal glucose reabsorption, leading to increased urinary glucose excretion and improved glycemic control. The drug is a small-molecule oral tablet positioned in the competitive SGLT2 inhibitor class.
Peak15.2 years to LOE
Early-stage product in peak lifecycle phase with TheracosBio; limited commercial data suggests modest market penetration relative to entrenched competitors.
Mechanism of Action
Sodium-Glucose Transporter 2 Inhibitors
Pharmacologic Class:
Sodium-Glucose Cotransporter 2 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BRENZAVVY offers exposure to a competitive, high-revenue therapeutic area (type 2 diabetes) and the challenge of differentiating a monotherapy in a mature market dominated by established leaders. The product's peak lifecycle stage and strong patent position (through 2041) provide 5–8 years of robust commercial opportunity before generic pressure, making it attractive for mid-career professionals seeking growth in a stable franchise.
Brand Manager
Worked on BRENZAVVY at TheracosBio? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.